Drugs that target the programmed cell death-1 (PD-1) receptor have shown 
promising antitumor activity in clinical trials, but it is not clear whether 
expression of the ligand PD-L1 is a biomarker for response. Increasingly, 
researchers say that PD-L1 expression is just one of many variables that may 
affect response to PD-1 blockade.